Endo International (NASDAQ:ENDP) (TSE:ENL) had its price target lowered by investment analysts at Canaccord Genuity from $17.00 to $15.00 in a report released on Wednesday, The Fly reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity’s price objective suggests a potential upside of 130.06% from the company’s previous close.
Several other research firms also recently commented on ENDP. Leerink Swann downgraded shares of Endo International from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 5th. Svb Leerink lowered shares of Endo International from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 5th. ValuEngine upgraded shares of Endo International from a “sell” rating to a “hold” rating in a report on Tuesday, March 12th. BidaskClub upgraded shares of Endo International from a “hold” rating to a “buy” rating in a report on Thursday, March 21st. Finally, Mizuho set a $9.00 target price on shares of Endo International and gave the company a “hold” rating in a research report on Tuesday. Three analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have given a buy rating to the stock. Endo International presently has an average rating of “Hold” and a consensus target price of $14.88.
ENDP traded down $0.09 during trading on Wednesday, reaching $6.52. 1,196,607 shares of the stock were exchanged, compared to its average volume of 3,179,066. The company has a market cap of $1.46 billion, a price-to-earnings ratio of 2.26 and a beta of 1.12. Endo International has a twelve month low of $5.92 and a twelve month high of $18.50.
Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Thursday, May 9th. The company reported $0.53 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.42 by $0.11. The business had revenue of $720.00 million for the quarter, compared to the consensus estimate of $692.31 million. Endo International had a negative net margin of 18.35% and a negative return on equity of 199.18%. The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.67 earnings per share. On average, analysts predict that Endo International will post 2.2 earnings per share for the current year.
Several institutional investors and hedge funds have recently modified their holdings of ENDP. Norges Bank bought a new position in shares of Endo International in the 4th quarter worth $21,218,000. Acadian Asset Management LLC lifted its stake in Endo International by 83,573.5% during the 1st quarter. Acadian Asset Management LLC now owns 771,470 shares of the company’s stock valued at $6,194,000 after acquiring an additional 770,548 shares in the last quarter. Canada Pension Plan Investment Board lifted its stake in Endo International by 143,723.6% during the 4th quarter. Canada Pension Plan Investment Board now owns 730,624 shares of the company’s stock valued at $5,333,000 after acquiring an additional 730,116 shares in the last quarter. Oregon Public Employees Retirement Fund bought a new position in Endo International during the 4th quarter valued at $76,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in Endo International by 24.8% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,900,414 shares of the company’s stock valued at $15,260,000 after acquiring an additional 378,182 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Recommended Story: What is a back-end load?
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.